Planning Trade-offs for SABR in Patients With 4 to 10 Metastases: A Substudy of the SABR-COMET-10 Randomized Trial

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.9K citations

Medicine, Oncology, Radiation Oncology +15

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Daniel R. Gomez, George R. Blumenschein, Mike Hernández et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Medical Oncology +7

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer

Puneeth Iyengar, Zabi Wardak, David E. Gerber et al. · JAMA Oncology · 2017 · 1K citations

Medicine, Oncology, Radiation Oncology +13

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Theo J. M. Ruers, Cornelis J.A. Punt, Frits van Coevorden et al. · Annals of Oncology · 2012 · 437 citations · Full text

Medicine, Oncology, Surgery +17

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma, Robert Olson, Stephen Harrow et al. · BMC Cancer · 2019 · 268 citations · Full text

Medicine, Oncology, Radiation Oncology +14